Skip to main content

Table 1 Baseline characteristics of patients by allocation

From: Methodological considerations for a randomised controlled trial of podiatry care in rheumatoid arthritis: lessons from an exploratory trial

Demographics and disease characteristics No intervention Podiatry
N 18 16
Female: n (%) 13 (72%) 12 (75%)
Age: years (SD) 64.6 (12.1) 56.8 (10.2)
Disease duration: years (SD) 16.7 (10.1) 14.1 (11.9)
DAS (0–10): median score (IQR) 4.3 (3.5,5.2) 3.7 (3.1,4.2)
HAQ score (0–3): median score (IQR) 1.04 (0.48,1.71) 0.75 (0.63,1.13)
BMI: median score (IQR) 27.0 (22.6,32.3) 27.0 (24.8,30.5)
Pharmacological management   
Analgesics: n (%) 8 (44%) 6 (38%)
NSAIDs: n (%) 9 (50%) 8 (50%)
DMARDs: n (%) 12 (67%) 14 (88%)
Biologic agent: n (%) 2 (11%) 1 (6%)
Corticosteroid: n (%) 5 (28%) 4 (25%)
Other: n (%) 2 (11%) 2 (13%)
Foot disease   
LFISIF (0–21): median score (IQR) 13 (12,14) 15 (12,16)
LFISAP (0–30) median score (IQR) 21 (16,26) 17 (15,24)
Function   
Walking speed (m/s): median score (IQR) 0.70 (0.40,1.09) 0.88 (0.76,1.00)
  1. DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; BMI, Body Mass Index; NSAIDs, Non-Steroidal Anti Inflammatory Drugs; DMARDs, Disease Modifying Anti-Rheumatic Drugs, LFIS, Leeds Foot Impairment Score (IF, Impairment/footwear subscale, AP, Activity limitation/participation restriction subscale). Values are presented as mean (standard deviation) or median (inter-quartile range).